{
  "state": "mississippi",
  "path": "title-title-41-public-health-41-1-1-41-149-11/chapter-chapter-147-individualized-investigative-treatment-41-147-1-",
  "sections": [
    {
      "id": "section-41-147-1",
      "number": "41-147-1",
      "heading": "DefinitionsSection 41-147-3 - Availability of individualized investigative treatment to eligible patients in eligible facilitiesSection 41-147-5 - Coverage for individualized investigative treatmentSection 41-147-7 - Liability for costs due to patient's death if proximately caused by individualized ",
      "text": "As used in this act, the following terms shall have the meanings ascribed herein:(a)\"Life-threatening or severely debilitating illness,\" means as it is defined in Section 312.81 of Title 21, Code of Federal Regulations (or any successor law or regulation, as applicable).(b)\"Eligible patient\" means an individual who meets the following conditions:(i)Has considered all other treatment options currently approved by the United States Food and Drug Administration;(ii)Has received a recommendation from his or her physician for an individualized investigational treatment, based on analysis of the patient's genomic sequence, human chromosomes, deoxyribonucleic acid, ribonucleic acid, genes, gene products (such as enzymes and other types of proteins), or metabolites;(iii)Has a life-threatening or severely debilitating illness, or serious disease or condition associated with morbidity that has a substantial impact on day-to-day functioning, attested to by the patient's treating physician;(iv)Has given written, informed consent for the use of the investigational drug, biological product, or device; and(v)Has documentation from his or her physician that he or she meets the requirements of this paragraph; or(vi)An individual who has documentation from his or her physician that the individual has been diagnosed with the human immunodeficiency virus (HIV).(c)\"Individualized investigational treatment\" means drugs, biological products, or devices that are unique to and produced exclusively for use for an individual patient, based on their own genetic profile, or long-acting injectable antiretroviral drugs for the treatment of patients with HIV.(d)\"Individualized investigational treatment\" includes, but is not limited to, individualized gene therapy antisense oligonucleotides (ASO) and individualized neoantigen vaccines. Individualized investigational treatment\" does not include any drug, biological product, or device derived from human primary or secondary embryonic stem cells or cell lines, or tissues or cells derived from abortion, but does include any drug, biological product, or device derived from human perinatal tissues, cells, and secreted factors not obtained from an abortion.(e)\"Written, informed consent\" means a written document that is signed by the patient; or if the patient is a minor, by any person authorized to consent under Section41-41-3; and attested to by the patient's physician and a witness and that, at a minimum, includes all of the following:(i)An explanation of the currently approved products and treatments for the illness, disease or condition from which the patient suffers;(ii)An attestation that the patient concurs with his or her physician in believing that all currently approved and conventionally recognized treatments are unlikely to prolong the patient's life;(iii)Clear identification of the specific proposed individualized investigational drug, biological product or device that the patient is seeking to use;(iv)A description of the potentially best and worst outcomes of using the individualized investigational drug, biological product, or device and a realistic description of the most likely outcome. The description shall include the possibility that new, unanticipated, different or worse symptoms might result and that death could be hastened by the proposed treatment. The description shall be based on the physician's knowledge of the proposed treatment in conjunction with an awareness of the patient's condition;(v)A statement that the patient's health plan or third party administrator and provider are not obligated to pay for any care or treatments consequent to the use of the individualized investigational drug, biological product, or device, unless they are specifically required to do so by law or contract;(vi)A statement that the patient's eligibility for hospice care may be withdrawn if the patient begins curative treatment with the individualized investigational drug, biological product, or device and that care may be reinstated if this treatment ends and the patient meets hospice eligibility requirements; and(vii)A statement that the patient understands that he or she is liable for all expenses consequent to the use of the individualized investigational drug, biological product, or device and that this liability extends to the patient's estate, unless a contract between the patient and the manufacturer of the drug, biological product, or device states otherwise.(f)\"Eligible facility\" means an institution that is operating under a Federal-wide Assurance (FWA) for the Protection of Human Subjects under42 U.S.C. 289(a)and 45 CFR Part 46 . and eligible facility is subject to the FWA laws, regulations, policies, and guidelines including renewals or updates.Added by Laws, 2024, ch. 432, SB 2858,§ 1, eff. 7/1/2024.\n\nAs used in this act, the following terms shall have the meanings ascribed herein:(a)\"Life-threatening or severely debilitating illness,\" means as it is defined in Section 312.81 of Title 21, Code of Federal Regulations (or any successor law or regulation, as applicable).(b)\"Eligible patient\" means an individual who meets the following conditions:(i)Has considered all other treatment options currently approved by the United States Food and Drug Administration;(ii)Has received a recommendation from his or her physician for an individualized investigational treatment, based on analysis of the patient's genomic sequence, human chromosomes, deoxyribonucleic acid, ribonucleic acid, genes, gene products (such as enzymes and other types of proteins), or metabolites;(iii)Has a life-threatening or severely debilitating illness, or serious disease or condition associated with morbidity that has a substantial impact on day-to-day functioning, attested to by the patient's treating physician;(iv)Has given written, informed consent for the use of the investigational drug, biological product, or device; and(v)Has documentation from his or her physician that he or she meets the requirements of this paragraph; or(vi)An individual who has documentation from his or her physician that the individual has been diagnosed with the human immunodeficiency virus (HIV).(c)\"Individualized investigational treatment\" means drugs, biological products, or devices that are unique to and produced exclusively for use for an individual patient, based on their own genetic profile, or long-acting injectable antiretroviral drugs for the treatment of patients with HIV.(d)\"Individualized investigational treatment\" includes, but is not limited to, individualized gene therapy antisense oligonucleotides (ASO) and individualized neoantigen vaccines. Individualized investigational treatment\" does not include any drug, biological product, or device derived from human primary or secondary embryonic stem cells or cell lines, or tissues or cells derived from abortion, but does include any drug, biological product, or device derived from human perinatal tissues, cells, and secreted factors not obtained from an abortion.(e)\"Written, informed consent\" means a written document that is signed by the patient; or if the patient is a minor, by any person authorized to consent under Section41-41-3; and attested to by the patient's physician and a witness and that, at a minimum, includes all of the following:(i)An explanation of the currently approved products and treatments for the illness, disease or condition from which the patient suffers;(ii)An attestation that the patient concurs with his or her physician in believing that all currently approved and conventionally recognized treatments are unlikely to prolong the patient's life;(iii)Clear identification of the specific proposed individualized investigational drug, biological product or device that the patient is seeking to use;(iv)A description of the potentially best and worst outcomes of using the individualized investigational drug, biological product, or device and a realistic description of the most likely outcome. The description shall include the possibility that new, unanticipated, different or worse symptoms might result and that death could be hastened by the proposed treatment. The description shall be based on the physician's knowledge of the proposed treatment in conjunction with an awareness of the patient's condition;(v)A statement that the patient's health plan or third party administrator and provider are not obligated to pay for any care or treatments consequent to the use of the individualized investigational drug, biological product, or device, unless they are specifically required to do so by law or contract;(vi)A statement that the patient's eligibility for hospice care may be withdrawn if the patient begins curative treatment with the individualized investigational drug, biological product, or device and that care may be reinstated if this treatment ends and the patient meets hospice eligibility requirements; and(vii)A statement that the patient understands that he or she is liable for all expenses consequent to the use of the individualized investigational drug, biological product, or device and that this liability extends to the patient's estate, unless a contract between the patient and the manufacturer of the drug, biological product, or device states otherwise.(f)\"Eligible facility\" means an institution that is operating under a Federal-wide Assurance (FWA) for the Protection of Human Subjects under42 U.S.C. 289(a)and 45 CFR Part 46 . and eligible facility is subject to the FWA laws, regulations, policies, and guidelines including renewals or updates.Added by Laws, 2024, ch. 432, SB 2858,§ 1, eff. 7/1/2024.\n\nAs used in this act, the following terms shall have the meanings ascribed herein:(a)\"Life-threatening or severely debilitating illness,\" means as it is defined in Section 312.81 of Title 21, Code of Federal Regulations (or any successor law or regulation, as applicable).(b)\"Eligible patient\" means an individual who meets the following conditions:(i)Has considered all other treatment options currently approved by the United States Food and Drug Administration;(ii)Has received a recommendation from his or her physician for an individualized investigational treatment, based on analysis of the patient's genomic sequence, human chromosomes, deoxyribonucleic acid, ribonucleic acid, genes, gene products (such as enzymes and other types of proteins), or metabolites;(iii)Has a life-threatening or severely debilitating illness, or serious disease or condition associated with morbidity that has a substantial impact on day-to-day functioning, attested to by the patient's treating physician;(iv)Has given written, informed consent for the use of the investigational drug, biological product, or device; and(v)Has documentation from his or her physician that he or she meets the requirements of this paragraph; or(vi)An individual who has documentation from his or her physician that the individual has been diagnosed with the human immunodeficiency virus (HIV).(c)\"Individualized investigational treatment\" means drugs, biological products, or devices that are unique to and produced exclusively for use for an individual patient, based on their own genetic profile, or long-acting injectable antiretroviral drugs for the treatment of patients with HIV.(d)\"Individualized investigational treatment\" includes, but is not limited to, individualized gene therapy antisense oligonucleotides (ASO) and individualized neoantigen vaccines. Individualized investigational treatment\" does not include any drug, biological product, or device derived from human primary or secondary embryonic stem cells or cell lines, or tissues or cells derived from abortion, but does include any drug, biological product, or device derived from human perinatal tissues, cells, and secreted factors not obtained from an abortion.(e)\"Written, informed consent\" means a written document that is signed by the patient; or if the patient is a minor, by any person authorized to consent under Section41-41-3; and attested to by the patient's physician and a witness and that, at a minimum, includes all of the following:(i)An explanation of the currently approved products and treatments for the illness, disease or condition from which the patient suffers;(ii)An attestation that the patient concurs with his or her physician in believing that all currently approved and conventionally recognized treatments are unlikely to prolong the patient's life;(iii)Clear identification of the specific proposed individualized investigational drug, biological product or device that the patient is seeking to use;(iv)A description of the potentially best and worst outcomes of using the individualized investigational drug, biological product, or device and a realistic description of the most likely outcome. The description shall include the possibility that new, unanticipated, different or worse symptoms might result and that death could be hastened by the proposed treatment. The description shall be based on the physician's knowledge of the proposed treatment in conjunction with an awareness of the patient's condition;(v)A statement that the patient's health plan or third party administrator and provider are not obligated to pay for any care or treatments consequent to the use of the individualized investigational drug, biological product, or device, unless they are specifically required to do so by law or contract;(vi)A statement that the patient's eligibility for hospice care may be withdrawn if the patient begins curative treatment with the individualized investigational drug, biological product, or device and that care may be reinstated if this treatment ends and the patient meets hospice eligibility requirements; and(vii)A statement that the patient understands that he or she is liable for all expenses consequent to the use of the individualized investigational drug, biological product, or device and that this liability extends to the patient's estate, unless a contract between the patient and the manufacturer of the drug, biological product, or device states otherwise.(f)\"Eligible facility\" means an institution that is operating under a Federal-wide Assurance (FWA) for the Protection of Human Subjects under42 U.S.C. 289(a)and 45 CFR Part 46 . and eligible facility is subject to the FWA laws, regulations, policies, and guidelines including renewals or updates.Added by Laws, 2024, ch. 432, SB 2858,§ 1, eff. 7/1/2024.\n\nAs used in this act, the following terms shall have the meanings ascribed herein:\n\nAdded by Laws, 2024, ch. 432, SB 2858,§ 1, eff. 7/1/2024.",
      "history": "",
      "source_url": "https://law.justia.com/codes/mississippi/title-41/chapter-147/section-41-147-1/"
    },
    {
      "id": "section-41-147-3",
      "number": "41-147-3",
      "heading": "Availability of individualized investigative treatment to eligible patients in eligible facilities",
      "text": "(1)A manufacturer operating within an eligible facility and pursuant to all applicable FWA laws and regulations may make available an individualized investigative treatment and an eligible patient may request an individualized investigational drug, biological product or device from an eligible facility or manufacturer operating within an eligible facility under this act. This act does not require that a manufacturer make available an individualized investigational drug, biological product, or device to an eligible patient.(2)An eligible facility or manufacturer operating within an eligible facility may do all of the following:(a)Provide an individualized investigational drug, biological product, or device to an eligible patient without receiving compensation; and(b)Require an eligible patient to pay the costs of, or the costs associated with, the manufacture of the investigational drug, biological product, or device.Added by Laws, 2024, ch. 432, SB 2858,§ 2, eff. 7/1/2024.\n\n(1)A manufacturer operating within an eligible facility and pursuant to all applicable FWA laws and regulations may make available an individualized investigative treatment and an eligible patient may request an individualized investigational drug, biological product or device from an eligible facility or manufacturer operating within an eligible facility under this act. This act does not require that a manufacturer make available an individualized investigational drug, biological product, or device to an eligible patient.(2)An eligible facility or manufacturer operating within an eligible facility may do all of the following:(a)Provide an individualized investigational drug, biological product, or device to an eligible patient without receiving compensation; and(b)Require an eligible patient to pay the costs of, or the costs associated with, the manufacture of the investigational drug, biological product, or device.Added by Laws, 2024, ch. 432, SB 2858,§ 2, eff. 7/1/2024.\n\n(1)A manufacturer operating within an eligible facility and pursuant to all applicable FWA laws and regulations may make available an individualized investigative treatment and an eligible patient may request an individualized investigational drug, biological product or device from an eligible facility or manufacturer operating within an eligible facility under this act. This act does not require that a manufacturer make available an individualized investigational drug, biological product, or device to an eligible patient.(2)An eligible facility or manufacturer operating within an eligible facility may do all of the following:(a)Provide an individualized investigational drug, biological product, or device to an eligible patient without receiving compensation; and(b)Require an eligible patient to pay the costs of, or the costs associated with, the manufacture of the investigational drug, biological product, or device.Added by Laws, 2024, ch. 432, SB 2858,§ 2, eff. 7/1/2024.\n\nAdded by Laws, 2024, ch. 432, SB 2858,§ 2, eff. 7/1/2024.",
      "history": "",
      "source_url": "https://law.justia.com/codes/mississippi/title-41/chapter-147/section-41-147-3/"
    },
    {
      "id": "section-41-147-5",
      "number": "41-147-5",
      "heading": "Coverage for individualized investigative treatment",
      "text": "(1)This act shall not be construed to expand the coverage required of an insurer under Title 83 of the Mississippi Code.(2)A health plan, third party administrator, or governmental agency may, but is not required to, provide coverage for the cost of an individualized investigational drug, biological product, or device, or the cost of services related to the use of an individualized investigational drug, biological product, or device under this act.(3)This act shall not be construed to require any governmental agency to pay costs associated with the use, care, or treatment of a patient with an individualized investigational drug, biological product, or device.(4)This act shall not be construed to require a licensed hospital or facility to provide new or additional services, unless approved by the hospital or facility.Added by Laws, 2024, ch. 432, SB 2858,§ 3, eff. 7/1/2024.\n\n(1)This act shall not be construed to expand the coverage required of an insurer under Title 83 of the Mississippi Code.(2)A health plan, third party administrator, or governmental agency may, but is not required to, provide coverage for the cost of an individualized investigational drug, biological product, or device, or the cost of services related to the use of an individualized investigational drug, biological product, or device under this act.(3)This act shall not be construed to require any governmental agency to pay costs associated with the use, care, or treatment of a patient with an individualized investigational drug, biological product, or device.(4)This act shall not be construed to require a licensed hospital or facility to provide new or additional services, unless approved by the hospital or facility.Added by Laws, 2024, ch. 432, SB 2858,§ 3, eff. 7/1/2024.\n\n(1)This act shall not be construed to expand the coverage required of an insurer under Title 83 of the Mississippi Code.(2)A health plan, third party administrator, or governmental agency may, but is not required to, provide coverage for the cost of an individualized investigational drug, biological product, or device, or the cost of services related to the use of an individualized investigational drug, biological product, or device under this act.(3)This act shall not be construed to require any governmental agency to pay costs associated with the use, care, or treatment of a patient with an individualized investigational drug, biological product, or device.(4)This act shall not be construed to require a licensed hospital or facility to provide new or additional services, unless approved by the hospital or facility.Added by Laws, 2024, ch. 432, SB 2858,§ 3, eff. 7/1/2024.\n\nAdded by Laws, 2024, ch. 432, SB 2858,§ 3, eff. 7/1/2024.",
      "history": "",
      "source_url": "https://law.justia.com/codes/mississippi/title-41/chapter-147/section-41-147-5/"
    },
    {
      "id": "section-41-147-7",
      "number": "41-147-7",
      "heading": "Liability for costs due to patient's death if proximately caused by individualized investigational treatment",
      "text": "If a patient's death is proximately caused by treatment with an individualized investigational drug, biological product, or device, the patient's estate, heirs, or devisees are not liable for any debt remaining after payment by insurance for charges directly incurred for said treatment. However, this provision does not provide an exemption to liability for charges for non-experimental treatments provided to the patient, including non-experimental treatments rendered to the patient due to complications or consequences of the experimental treatment.Added by Laws, 2024, ch. 432, SB 2858,§ 4, eff. 7/1/2024.\n\nIf a patient's death is proximately caused by treatment with an individualized investigational drug, biological product, or device, the patient's estate, heirs, or devisees are not liable for any debt remaining after payment by insurance for charges directly incurred for said treatment. However, this provision does not provide an exemption to liability for charges for non-experimental treatments provided to the patient, including non-experimental treatments rendered to the patient due to complications or consequences of the experimental treatment.Added by Laws, 2024, ch. 432, SB 2858,§ 4, eff. 7/1/2024.\n\nIf a patient's death is proximately caused by treatment with an individualized investigational drug, biological product, or device, the patient's estate, heirs, or devisees are not liable for any debt remaining after payment by insurance for charges directly incurred for said treatment. However, this provision does not provide an exemption to liability for charges for non-experimental treatments provided to the patient, including non-experimental treatments rendered to the patient due to complications or consequences of the experimental treatment.Added by Laws, 2024, ch. 432, SB 2858,§ 4, eff. 7/1/2024.\n\nIf a patient's death is proximately caused by treatment with an individualized investigational drug, biological product, or device, the patient's estate, heirs, or devisees are not liable for any debt remaining after payment by insurance for charges directly incurred for said treatment. However, this provision does not provide an exemption to liability for charges for non-experimental treatments provided to the patient, including non-experimental treatments rendered to the patient due to complications or consequences of the experimental treatment.\n\nAdded by Laws, 2024, ch. 432, SB 2858,§ 4, eff. 7/1/2024.",
      "history": "",
      "source_url": "https://law.justia.com/codes/mississippi/title-41/chapter-147/section-41-147-7/"
    },
    {
      "id": "section-41-147-9",
      "number": "41-147-9",
      "heading": "Licensing and certification authorities prohibited from certain actions",
      "text": "(1)A licensing board or disciplinary subcommittee shall not revoke, fail to renew, suspend, or take any action against a health care provider's license, and based solely on the health care provider's recommendations to an eligible patient regarding access to or treatment with an individualized investigational drug, biological product or device.(2)An entity responsible for Medicare certification shall not take action against a health care provider's Medicare certification based solely on the health care provider's recommendation that a patient have access to an individualized investigational drug, biological product, or device.Added by Laws, 2024, ch. 432, SB 2858,§ 5, eff. 7/1/2024.\n\n(1)A licensing board or disciplinary subcommittee shall not revoke, fail to renew, suspend, or take any action against a health care provider's license, and based solely on the health care provider's recommendations to an eligible patient regarding access to or treatment with an individualized investigational drug, biological product or device.(2)An entity responsible for Medicare certification shall not take action against a health care provider's Medicare certification based solely on the health care provider's recommendation that a patient have access to an individualized investigational drug, biological product, or device.Added by Laws, 2024, ch. 432, SB 2858,§ 5, eff. 7/1/2024.\n\n(1)A licensing board or disciplinary subcommittee shall not revoke, fail to renew, suspend, or take any action against a health care provider's license, and based solely on the health care provider's recommendations to an eligible patient regarding access to or treatment with an individualized investigational drug, biological product or device.(2)An entity responsible for Medicare certification shall not take action against a health care provider's Medicare certification based solely on the health care provider's recommendation that a patient have access to an individualized investigational drug, biological product, or device.Added by Laws, 2024, ch. 432, SB 2858,§ 5, eff. 7/1/2024.\n\nAdded by Laws, 2024, ch. 432, SB 2858,§ 5, eff. 7/1/2024.",
      "history": "",
      "source_url": "https://law.justia.com/codes/mississippi/title-41/chapter-147/section-41-147-9/"
    },
    {
      "id": "section-41-147-11",
      "number": "41-147-11",
      "heading": "Access to individualized investigational drug, biological product, or device",
      "text": "(1)An official, employee, or agent of this state shall not block or attempt to block an eligible patient's access to an individualized investigational drug, biological product, or device.(2)Counseling, advice, or a recommendation consistent with medical standards of care from a licensed health care provider shall not be considered a violation of this section.Added by Laws, 2024, ch. 432, SB 2858,§ 6, eff. 7/1/2024.\n\n(1)An official, employee, or agent of this state shall not block or attempt to block an eligible patient's access to an individualized investigational drug, biological product, or device.(2)Counseling, advice, or a recommendation consistent with medical standards of care from a licensed health care provider shall not be considered a violation of this section.Added by Laws, 2024, ch. 432, SB 2858,§ 6, eff. 7/1/2024.\n\n(1)An official, employee, or agent of this state shall not block or attempt to block an eligible patient's access to an individualized investigational drug, biological product, or device.(2)Counseling, advice, or a recommendation consistent with medical standards of care from a licensed health care provider shall not be considered a violation of this section.Added by Laws, 2024, ch. 432, SB 2858,§ 6, eff. 7/1/2024.\n\nAdded by Laws, 2024, ch. 432, SB 2858,§ 6, eff. 7/1/2024.",
      "history": "",
      "source_url": "https://law.justia.com/codes/mississippi/title-41/chapter-147/section-41-147-11/"
    },
    {
      "id": "section-41-147-13",
      "number": "41-147-13",
      "heading": "Private cause of action",
      "text": "This act does not create a private cause of action against a manufacturer of an individualized investigational drug, biological product, or device or against any other person or entity involved in the care of an eligible patient using the individualized investigational drug, biological product, or device for any harm done to the eligible patient resulting from the individualized investigational drug, biological product, or device, if the manufacturer or other person or entity is complying in good faith with the terms of this act and has exercised reasonable care.Added by Laws, 2024, ch. 432, SB 2858,§ 7, eff. 7/1/2024.\n\nThis act does not create a private cause of action against a manufacturer of an individualized investigational drug, biological product, or device or against any other person or entity involved in the care of an eligible patient using the individualized investigational drug, biological product, or device for any harm done to the eligible patient resulting from the individualized investigational drug, biological product, or device, if the manufacturer or other person or entity is complying in good faith with the terms of this act and has exercised reasonable care.Added by Laws, 2024, ch. 432, SB 2858,§ 7, eff. 7/1/2024.\n\nThis act does not create a private cause of action against a manufacturer of an individualized investigational drug, biological product, or device or against any other person or entity involved in the care of an eligible patient using the individualized investigational drug, biological product, or device for any harm done to the eligible patient resulting from the individualized investigational drug, biological product, or device, if the manufacturer or other person or entity is complying in good faith with the terms of this act and has exercised reasonable care.Added by Laws, 2024, ch. 432, SB 2858,§ 7, eff. 7/1/2024.\n\nThis act does not create a private cause of action against a manufacturer of an individualized investigational drug, biological product, or device or against any other person or entity involved in the care of an eligible patient using the individualized investigational drug, biological product, or device for any harm done to the eligible patient resulting from the individualized investigational drug, biological product, or device, if the manufacturer or other person or entity is complying in good faith with the terms of this act and has exercised reasonable care.\n\nAdded by Laws, 2024, ch. 432, SB 2858,§ 7, eff. 7/1/2024.",
      "history": "",
      "source_url": "https://law.justia.com/codes/mississippi/title-41/chapter-147/section-41-147-13/"
    }
  ]
}